Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap blue chip stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. The terms of the agreement entail that Vivtex would license select oral drug-delivery technologies to Novo Nordisk A/S (NYSE:NVO), with Vivtex eligible to receive upfront consideration, research funding, and milestone payments totalling up to $2.1 billion, and tiered royalties on future product sales. Vivtex’s platform combines multiple proprietary gastrointestinal screening assays, drug-delivery technologies, and computational simulation and AI capabilities for the optimization of the oral delivery of biologic medicines.

Management further reported that the primary goal of the collaboration is to allow the oral delivery of biologic drug candidates traditionally limited to injectable administration because of poor absorption in the gastrointestinal tract. The partnership thus brings together Novo Nordisk’s (NYSE:NVO) expertise in peptide and protein therapeutics and Vivtex’s proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics. Novo Nordisk A/S (NYSE:NVO) further reported that following research and formulation selection, it will assume responsibility for regulatory activities, global development, manufacturing, and commercialization of any resulting products.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.